ONIVYDE® with oxaliplatin, fluorouracil and leucovorin will be included in Taiwan NHI for first-line treatment of metastatic pancreatic adenocarcinoma

PharmaEngine announces first patient dosed in PEP08 Phase I clinical trial for solid tumor cancers

PharmaEngine recognized as one of 2025 Taiwan Best-in-Class Companies by Taiwan Institute of Directors